Read more

March 15, 2021
2 min read
Save

AF screening with wearable monitor beneficial in older individuals with hypertension

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Atrial fibrillation screening with wearable continuous electrocardiographic monitors was well tolerated, increased AF detection and sometimes prompted anticoagulant therapy among older individuals with hypertension, researchers reported.

Perspective from Steven A. Lubitz, MD, MPH

“If screening can effectively detect sufficient numbers of individuals with AF and trigger initiation of oral anticoagulation, many strokes could potentially be prevented,” David J. Gladstone, MD, PhD, scientist at Sunnybrook Research Institute in Toronto and associate professor of medicine at the University of Toronto, and colleagues wrote in JAMA Cardiology.

Graphical depiction of data presented in article
AF screening with wearable continuous electrocardiographic monitors was well tolerated, increased AF detection and sometimes prompted anticoagulant therapy among older individuals with hypertension. Data were derived from Gladstone DJ, et al. JAMA Cardiol. 2021;doi:10.1001/jamacardio.2021.0038.

SCREEN-AF, a multicenter randomized clinical trial, included 856 participants aged 75 years or older (mean age, 80 years; 57% women) with hypertension without known AF from 48 primary care practices from April 2015 to March 2019. Participants were randomly assigned to the control group, which received standard care defined as routine clinical follow-up and a pulse check and heart auscultation at baseline and 6 months, or the screening group, which received a 2-week continuous ECG patch monitor at baseline and at 3 months along with standard care.

Participants in the screening group also received an automated home BP machine with AF screening capability and were instructed to use it twice daily during the periods of continuous ECG monitoring.

The primary outcome of the study was continuous ECG-detected AF or clinically detected AF within 6 months. Secondary outcomes included anticoagulant use, device adherence and AF detection by BP monitors.

Median continuous ECG wear time in the cohort was 27.4 days out of 28. The monitor detected AF among 5.3% of participants in the screening group. By contrast, 0.5% of controls had AF detected (absolute difference = 4.8 percentage points; 95% CI, 2.6-7; P < .001). Of participants with AF detected by the monitor, the median total time in AF was 6.3 hours and median duration of longest AF episode was 5.7 hours.

Researchers initiated anticoagulation therapy in 75% of participants with continuous ECG-detected AF. In total, anticoagulation therapy was prescribed for 4.1% of participants in the screening group compared with 0.9% of participants in the control group (absolute difference = 3.2 percentage points; 95% CI, 1.1-5.3; P = .003).

Twice-daily screening for AF using the home BP monitor had a sensitivity of 35%, a specificity of 81%, a positive predictive value of 8.9% and a negative predictive value of 95.9%

Discontinuation of the continuous ECG monitor because of adverse skin reactions occurred among 1.2% of participants.

“Our trial strengthens the evidence supporting the effectiveness of screening for early detection of AF,” Gladstone and colleagues wrote.